Cogent Biosciences, Inc.

NasdaqGS:COGT Stock Report

Market Cap: US$5.6b

Cogent Biosciences Valuation

Is COGT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of COGT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate COGT's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate COGT's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COGT?

Key metric: As COGT is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for COGT. This is calculated by dividing COGT's market cap by their current book value.
What is COGT's PB Ratio?
PB Ratio28.6x
BookUS$194.55m
Market CapUS$5.59b

Price to Book Ratio vs Peers

How does COGT's PB Ratio compare to its peers?

The above table shows the PB ratio for COGT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average11.1x
ALKS Alkermes
3.2x15.51%US$5.8b
PTGX Protagonist Therapeutics
7.9x46.02%US$5.2b
MIRM Mirum Pharmaceuticals
20.9x55.56%US$6.0b
CAI Caris Life Sciences
12.2x64.15%US$6.1b
COGT Cogent Biosciences
28.6x56.86%US$5.6b

Price-To-Book vs Peers: COGT is expensive based on its Price-To-Book Ratio (28.6x) compared to the peer average (11x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does COGT's PB Ratio compare vs other companies in the US Biotechs Industry?

64 CompaniesPrice / BookEstimated GrowthMarket Cap
NKTX Nkarta
0.4x-2.70%US$142.06m
XBIT XBiotech
0.4xn/aUS$72.26m
ETHZ ETHZilla
0.1xn/aUS$61.60m
PMVP PMV Pharmaceuticals
0.5x2.71%US$59.60m
COGT 28.6xIndustry Avg. 2.6xNo. of Companies71PB0246810+
64 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: COGT is expensive based on its Price-To-Book Ratio (28.6x) compared to the US Biotechs industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is COGT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COGT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio28.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate COGT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COGT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$36.53
US$52.58
+43.95%
20.31%US$72.00US$34.00n/a12
Feb ’27US$35.91
US$50.75
+41.33%
17.61%US$67.00US$34.00n/a12
Jan ’27US$35.52
US$49.18
+38.46%
18.61%US$67.00US$34.00n/a11
Dec ’26US$39.76
US$47.18
+18.67%
19.36%US$65.00US$34.00n/a11
Nov ’26US$16.30
US$23.00
+41.10%
39.45%US$44.00US$11.00n/a12
Oct ’26US$14.13
US$21.09
+49.26%
28.98%US$30.00US$11.00n/a11
Sep ’26US$12.08
US$20.36
+68.57%
26.76%US$30.00US$11.00n/a11
Aug ’26US$11.40
US$18.91
+65.87%
29.18%US$29.00US$9.00n/a11
Jul ’26US$7.22
US$16.27
+125.38%
31.89%US$25.00US$7.00n/a11
Jun ’26US$5.44
US$16.27
+199.13%
31.89%US$25.00US$7.00n/a11
May ’26US$5.63
US$16.50
+193.07%
29.47%US$24.00US$8.00n/a10
Apr ’26US$5.79
US$16.50
+184.97%
29.47%US$24.00US$8.00n/a10
Mar ’26US$7.53
US$16.50
+119.12%
29.47%US$24.00US$8.00n/a10
Feb ’26US$9.31
US$16.50
+77.23%
25.61%US$23.00US$10.00US$35.9110
Jan ’26US$7.80
US$16.80
+115.38%
24.66%US$23.00US$10.00US$35.5210
Dec ’25US$9.51
US$16.36
+72.07%
22.91%US$23.00US$10.00US$39.7611
Nov ’25US$11.72
US$16.45
+40.40%
21.58%US$22.00US$10.00US$16.3011
Oct ’25US$10.75
US$16.64
+54.76%
21.49%US$22.00US$10.00US$14.1311
Sep ’25US$10.74
US$16.36
+52.36%
25.96%US$22.00US$8.00US$12.0811
Aug ’25US$9.36
US$17.18
+83.57%
30.17%US$26.00US$8.00US$11.4011
Jul ’25US$8.94
US$17.18
+92.19%
30.17%US$26.00US$8.00US$7.2211
Jun ’25US$8.01
US$17.18
+114.50%
30.17%US$26.00US$8.00US$5.4411
May ’25US$6.93
US$16.70
+140.98%
31.12%US$26.00US$8.00US$5.6310
Apr ’25US$6.90
US$16.82
+143.74%
29.55%US$26.00US$8.00US$5.7911
Mar ’25US$7.23
US$16.82
+132.62%
29.55%US$26.00US$8.00US$7.5311
Feb ’25US$4.48
US$16.30
+263.84%
32.47%US$26.00US$5.00US$9.3110
US$52.58
Fair Value
30.5% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/13 22:56
End of Day Share Price 2026/02/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cogent Biosciences, Inc. is covered by 22 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Joel BeattyBaird
David LebowitzCitigroup Inc